(Photo Courtesy: www.cultofandroid.com)
The drug is sold under the name Vfend in the US.
The victory comes in after Ranbaxy, GM Pharma, Natco Pharma, and Ms Reena Manoharan, filed opposition against Pfizer claiming that ‘the subject matter of the application is not novel, the matter lacks innovation, its utility is not substantive, its claims are indefinite and that no patent can be granted for a combination of known substances'.
Pfizer disregarded the objectionable claims made by all the four parties.
"The composition is industrially useful in the preparation of medicaments for the treatment of fatal fungal infection and the opposition arguments on non-patentability of the innovation and prior claiming of the invention are not sustainable", said the deputy controller of Patents and Designs to Business Standard.